[{"id":"a7c4f9e4-84af-4d2b-9a47-edc69ca3a38e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07476729","created_at":"2026-03-28T01:40:41.936Z","updated_at":"2026-03-28T01:40:41.936Z","phase":"Phase 3","brief_title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","source_id_and_acronym":"NCT07476729","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" CD22","pipe":" | ","alterations":" CD19 positive • CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 03/31/2033","primary_completion_date":" 03/31/2033","study_txt":" Completion: 03/31/2033","study_completion_date":" 03/31/2033","last_update_posted":"2026-03-17"},{"id":"ac4afb38-f9f0-4fe8-a6ec-8ae6a59cd318","acronym":"A041703","url":"https://clinicaltrials.gov/study/NCT03739814","created_at":"2021-01-18T18:19:08.468Z","updated_at":"2025-02-25T12:27:03.899Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03739814 - A041703","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22","pipe":" | ","alterations":" CD22 positive","tags":["ABL1 • BCR • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 05/08/2019","start_date":" 05/08/2019","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-24"},{"id":"64862772-4e2d-4d09-a25e-0a3cd662c549","acronym":"AALL1621","url":"https://clinicaltrials.gov/study/NCT02981628","created_at":"2021-01-18T14:40:03.526Z","updated_at":"2025-02-25T15:10:29.659Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02981628 - AALL1621","lead_sponsor":"Children's Oncology Group","biomarkers":" KMT2A • CD22","pipe":" | ","alterations":" MLL rearrangement • CD22 expression","tags":["KMT2A • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/19/2017","start_date":" 06/19/2017","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-13"},{"id":"0dfdbda7-3ab9-4117-8538-4a9b1997b0a3","acronym":"NCI-2018-00936","url":"https://clinicaltrials.gov/study/NCT03441061","created_at":"2021-01-18T16:58:19.322Z","updated_at":"2025-02-25T16:37:03.930Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease","source_id_and_acronym":"NCT03441061 - NCI-2018-00936","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/15/2018","start_date":" 02/15/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-06"},{"id":"3615e982-327f-4793-b8ff-fdb95f9f33a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03856216","created_at":"2021-01-18T19:01:48.041Z","updated_at":"2025-02-25T16:52:26.547Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation","source_id_and_acronym":"NCT03856216","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD22 • HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["CD22 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • methotrexate • Besponsa (inotuzumab ozogamicin) • bendamustine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 10/28/2019","start_date":" 10/28/2019","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"ec3e743e-1b1e-4a2e-a3aa-858146aacd86","acronym":"","url":"https://clinicaltrials.gov/study/NCT05597085","created_at":"2022-10-27T15:58:40.495Z","updated_at":"2025-02-25T16:54:31.973Z","phase":"","brief_title":"A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment","source_id_and_acronym":"NCT05597085","lead_sponsor":"Pfizer","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 03/08/2023","start_date":" 03/08/2023","primary_txt":" Primary completion: 07/10/2023","primary_completion_date":" 07/10/2023","study_txt":" Completion: 07/10/2023","study_completion_date":" 07/10/2023","last_update_posted":"2025-02-04"},{"id":"6c3d7185-da62-4572-ad36-41e11a25a6bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687032","created_at":"2023-01-17T14:59:23.664Z","updated_at":"2024-07-02T16:34:59.887Z","phase":"Phase 4","brief_title":"A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05687032","lead_sponsor":"Pfizer","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/24/2023","start_date":" 02/24/2023","primary_txt":" Primary completion: 08/07/2024","primary_completion_date":" 08/07/2024","study_txt":" Completion: 11/07/2025","study_completion_date":" 11/07/2025","last_update_posted":"2024-05-31"},{"id":"30181726-4a7a-4641-822a-3105dcd88382","acronym":"","url":"https://clinicaltrials.gov/study/NCT05303792","created_at":"2022-03-31T17:52:41.961Z","updated_at":"2024-07-02T16:35:01.827Z","phase":"Phase 2","brief_title":"Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT05303792","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD20 • CD22","pipe":" | ","alterations":" CD20 expression • CD22 positive","tags":["CD20 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/27/2023","start_date":" 02/27/2023","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-05-23"},{"id":"b927a829-cf0c-477b-9e90-8e3922097562","acronym":"","url":"https://clinicaltrials.gov/study/NCT03150693","created_at":"2021-01-18T15:31:43.755Z","updated_at":"2024-07-02T16:35:01.768Z","phase":"Phase 3","brief_title":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03150693","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ABL1 • BCR • CD20 • CD22 • ITGB1","pipe":" | ","alterations":" CD20 positive • CD22 positive","tags":["ABL1 • BCR • CD20 • CD22 • ITGB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Besponsa (inotuzumab ozogamicin) • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • cyclophosphamide intravenous"],"overall_status":"Suspended","enrollment":" Enrollment 310","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-05-23"},{"id":"3bb3cbaf-b275-4098-8e50-b212d3de0ff5","acronym":"cRIB","url":"https://clinicaltrials.gov/study/NCT05645718","created_at":"2022-12-09T14:57:54.671Z","updated_at":"2024-07-02T16:35:06.157Z","phase":"Phase 2","brief_title":"Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","source_id_and_acronym":"NCT05645718 - cRIB","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • Neulasta (pegfilgrastim) • Depocyte (liposomal cytarabine)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-05-03"},{"id":"77accf55-b1ad-4e14-aada-f3a5e55d16c9","acronym":"EU PIP Study","url":"https://clinicaltrials.gov/study/NCT05748171","created_at":"2023-02-28T13:01:32.364Z","updated_at":"2024-07-02T16:35:06.949Z","phase":"Phase 2","brief_title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to ","source_id_and_acronym":"NCT05748171 - EU PIP Study","lead_sponsor":"Pfizer","biomarkers":" TP53 • KMT2A • CD22 • TCF3 • PBX1","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement • CD22 positive","tags":["TP53 • KMT2A • CD22 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/17/2023","start_date":" 05/17/2023","primary_txt":" Primary completion: 07/11/2028","primary_completion_date":" 07/11/2028","study_txt":" Completion: 07/09/2031","study_completion_date":" 07/09/2031","last_update_posted":"2024-04-30"},{"id":"05e37930-8cbd-43e9-89a2-63149b04e396","acronym":"","url":"https://clinicaltrials.gov/study/NCT03913559","created_at":"2021-01-18T19:15:34.393Z","updated_at":"2024-07-02T16:35:08.745Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","source_id_and_acronym":"NCT03913559","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • methotrexate • Besponsa (inotuzumab ozogamicin) • methylprednisolone sodium succinate"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/14/2019","start_date":" 05/14/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-19"},{"id":"0414e928-a316-42a5-8719-34e96c7da49c","acronym":"INO-FIRST","url":"https://clinicaltrials.gov/study/NCT06025682","created_at":"2023-09-06T14:09:39.551Z","updated_at":"2024-07-02T16:35:10.034Z","phase":"","brief_title":"Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO","source_id_and_acronym":"NCT06025682 - INO-FIRST","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 04/04/2024","start_date":" 04/04/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-11"},{"id":"6a54e9ca-ab14-4985-b527-5f222345e52f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04307576","created_at":"2021-01-18T20:53:16.021Z","updated_at":"2024-07-02T16:35:14.109Z","phase":"Phase 3","brief_title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","source_id_and_acronym":"NCT04307576","lead_sponsor":"Mats Heyman","biomarkers":" MYC • BCL2 • KMT2A","pipe":" | ","alterations":" MYC rearrangement + BCL2 rearrangement • MLL rearrangement • MYC rearrangement • MYC translocation • BCL2 rearrangement","tags":["MYC • BCL2 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement + BCL2 rearrangement • MLL rearrangement • MYC rearrangement • MYC translocation • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • doxorubicin hydrochloride • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • thioguanine"],"overall_status":"Recruiting","enrollment":" Enrollment 6430","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2032","study_completion_date":" 06/30/2032","last_update_posted":"2024-03-19"},{"id":"3d90ab54-ff08-4d6e-8285-06ffa9b82ff3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03104491","created_at":"2021-01-18T15:17:48.325Z","updated_at":"2024-07-02T16:35:16.971Z","phase":"Phase 1/2","brief_title":"Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia","source_id_and_acronym":"NCT03104491","lead_sponsor":"Leland Metheny","biomarkers":" BCL2 • BCL6 • CD22","pipe":" | ","alterations":" BCL6 rearrangement • CD22 positive • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • CD22 positive • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-02-29"},{"id":"620a7e24-02f5-4bea-9025-a841dcb93aa9","acronym":"NCI-2011-01123","url":"https://clinicaltrials.gov/study/NCT01371630","created_at":"2022-06-23T11:54:23.630Z","updated_at":"2024-07-02T16:35:25.100Z","phase":"Phase 1/2","brief_title":"Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT01371630 - NCI-2011-01123","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine"],"overall_status":"Recruiting","enrollment":" Enrollment 276","initiation":"Initiation: 08/26/2011","start_date":" 08/26/2011","primary_txt":" Primary completion: 12/25/2025","primary_completion_date":" 12/25/2025","study_txt":" Completion: 12/25/2025","study_completion_date":" 12/25/2025","last_update_posted":"2023-12-27"},{"id":"47a91841-a46b-498c-8a05-c78c3450d849","acronym":"","url":"https://clinicaltrials.gov/study/NCT03677596","created_at":"2021-01-18T18:02:08.633Z","updated_at":"2024-07-02T16:35:28.361Z","phase":"Phase 4","brief_title":"A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients","source_id_and_acronym":"NCT03677596","lead_sponsor":"Pfizer","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 102","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 09/21/2022","primary_completion_date":" 09/21/2022","study_txt":" Completion: 05/26/2023","study_completion_date":" 05/26/2023","last_update_posted":"2023-11-22"},{"id":"c6d4f78d-e9fb-44fb-b084-86b60a1d4509","acronym":"","url":"https://clinicaltrials.gov/study/NCT06087419","created_at":"2023-10-17T15:12:56.219Z","updated_at":"2024-07-02T16:35:30.632Z","phase":"Phase 1/2","brief_title":"A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients","source_id_and_acronym":"NCT06087419","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Besponsa (inotuzumab ozogamicin) • Epidaza (chidamide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-11-02"},{"id":"ed012c2c-cb0c-4ee4-b58a-67318a132454","acronym":"","url":"https://clinicaltrials.gov/study/NCT05940961","created_at":"2023-07-12T16:10:06.373Z","updated_at":"2024-07-02T16:35:37.355Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL","source_id_and_acronym":"NCT05940961","lead_sponsor":"Sheng-Li Xue, MD","biomarkers":" ABL1 • CD22","pipe":"","alterations":" ","tags":["ABL1 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-09-12"},{"id":"814e7ac6-45cf-46b6-b5f8-c3e997f1b25c","acronym":"EWALL-INO","url":"https://clinicaltrials.gov/study/NCT03249870","created_at":"2021-01-18T16:03:23.303Z","updated_at":"2024-07-02T16:35:38.086Z","phase":"Phase 2","brief_title":"Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL","source_id_and_acronym":"NCT03249870 - EWALL-INO","lead_sponsor":"Versailles Hospital","biomarkers":" ABL1 • BCR • CD22","pipe":" | ","alterations":" CD22 expression","tags":["ABL1 • BCR • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 12/28/2017","start_date":" 12/28/2017","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-09-06"},{"id":"34cdff59-a647-4371-a823-819a079db705","acronym":"","url":"https://clinicaltrials.gov/study/NCT04747912","created_at":"2021-02-10T14:56:01.167Z","updated_at":"2024-07-02T16:35:39.011Z","phase":"Phase 2","brief_title":"Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)","source_id_and_acronym":"NCT04747912","lead_sponsor":"University of Chicago","biomarkers":" ABL1 • BCR • CD22","pipe":" | ","alterations":" CD22 expression","tags":["ABL1 • BCR • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Iclusig (ponatinib) • Besponsa (inotuzumab ozogamicin) • vincristine"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/02/2021","start_date":" 03/02/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-08-25"},{"id":"df56bed1-a43b-40d3-baea-ecf1d6a1b137","acronym":"ALL 001","url":"https://clinicaltrials.gov/study/NCT03962465","created_at":"2021-01-18T19:29:49.915Z","updated_at":"2024-07-02T16:35:39.386Z","phase":"Phase 1","brief_title":"Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL","source_id_and_acronym":"NCT03962465 - ALL 001","lead_sponsor":"University of Virginia","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • daunorubicin • Oncaspar liquid (pegaspargase)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 07/22/2022","start_date":" 07/22/2022","primary_txt":" Primary completion: 07/15/2023","primary_completion_date":" 07/15/2023","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-08-22"},{"id":"527397ee-a21a-4630-81bf-27f9c9bfe907","acronym":"","url":"https://clinicaltrials.gov/study/NCT05016947","created_at":"2021-08-23T12:53:04.157Z","updated_at":"2024-07-02T16:35:42.681Z","phase":"Phase 1","brief_title":"Venetoclax Plus Inotuzumab for B-ALL","source_id_and_acronym":"NCT05016947","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/24/2021","start_date":" 09/24/2021","primary_txt":" Primary completion: 07/23/2024","primary_completion_date":" 07/23/2024","study_txt":" Completion: 06/23/2026","study_completion_date":" 06/23/2026","last_update_posted":"2023-07-18"},{"id":"695c1a45-9603-4f8e-b6ce-75995a62ee90","acronym":"","url":"https://clinicaltrials.gov/study/NCT02311998","created_at":"2021-01-17T18:01:29.030Z","updated_at":"2024-07-02T16:35:42.833Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML","source_id_and_acronym":"NCT02311998","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • CD22","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 04/16/2015","start_date":" 04/16/2015","primary_txt":" Primary completion: 03/23/2022","primary_completion_date":" 03/23/2022","study_txt":" Completion: 03/23/2022","study_completion_date":" 03/23/2022","last_update_posted":"2023-07-17"}]